KR102447769B1 - 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도 - Google Patents

발베나진 토실산염의 결정형 및 그 제조 방법 및 용도 Download PDF

Info

Publication number
KR102447769B1
KR102447769B1 KR1020207021772A KR20207021772A KR102447769B1 KR 102447769 B1 KR102447769 B1 KR 102447769B1 KR 1020207021772 A KR1020207021772 A KR 1020207021772A KR 20207021772 A KR20207021772 A KR 20207021772A KR 102447769 B1 KR102447769 B1 KR 102447769B1
Authority
KR
South Korea
Prior art keywords
crystalline form
present
drug
crystalline
formulation
Prior art date
Application number
KR1020207021772A
Other languages
English (en)
Korean (ko)
Other versions
KR20200103781A (ko
Inventor
민후아 첸
얀펑 장
차오휘 양
춘시앙 황
Original Assignee
크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. filed Critical 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디.
Publication of KR20200103781A publication Critical patent/KR20200103781A/ko
Application granted granted Critical
Publication of KR102447769B1 publication Critical patent/KR102447769B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207021772A 2017-12-26 2018-12-26 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도 KR102447769B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711436859.7 2017-12-26
CN201711436859 2017-12-26
PCT/CN2018/124039 WO2019129100A1 (zh) 2017-12-26 2018-12-26 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
KR20200103781A KR20200103781A (ko) 2020-09-02
KR102447769B1 true KR102447769B1 (ko) 2022-09-26

Family

ID=67066620

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207021772A KR102447769B1 (ko) 2017-12-26 2018-12-26 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도

Country Status (7)

Country Link
US (1) US11339158B2 (de)
EP (1) EP3733666B1 (de)
JP (1) JP7212958B2 (de)
KR (1) KR102447769B1 (de)
CN (1) CN110621674B (de)
CA (1) CA3086611C (de)
WO (1) WO2019129100A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
CA3148302A1 (en) * 2019-08-12 2021-02-18 Shandong Luye Pharmaceutical Co., Ltd. Vmat2 inhibitor and preparation method therefor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075340A1 (en) * 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080022351A1 (en) 2006-07-06 2008-01-24 Martin Nohr Streaming method and apparatus
CA2668689C (en) 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
CN113413385A (zh) 2014-02-07 2021-09-21 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
IL248745B (en) 2014-05-06 2022-07-01 Neurocrine Biosciences (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza
MX2017017015A (es) 2015-06-23 2018-02-26 Neurocrine Biosciences Inc Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
HUE059065T2 (hu) 2015-12-23 2022-10-28 Neurocrine Biosciences Inc Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
CA3051832A1 (en) 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors
US10954235B2 (en) * 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TW201919622A (zh) 2017-09-21 2019-06-01 美商紐羅克里生物科學有限公司 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組
CN109528665A (zh) 2017-09-21 2019-03-29 浙江京新药业股份有限公司 一种治疗迟发型运动障碍的药物的口崩片及其制备方法
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
WO2019104141A1 (en) 2017-11-22 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state form of valbenazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075340A1 (en) * 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof

Also Published As

Publication number Publication date
EP3733666B1 (de) 2022-09-21
CN110621674B (zh) 2022-03-29
CA3086611A1 (en) 2019-07-04
WO2019129100A1 (zh) 2019-07-04
EP3733666A4 (de) 2021-03-03
US11339158B2 (en) 2022-05-24
US20210078993A1 (en) 2021-03-18
CA3086611C (en) 2023-07-25
JP2021507927A (ja) 2021-02-25
JP7212958B2 (ja) 2023-01-26
KR20200103781A (ko) 2020-09-02
EP3733666A1 (de) 2020-11-04
CN110621674A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
JP7179049B2 (ja) オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
MX2014004201A (es) R(+)-n-metil-propargil-aminoindano.
EP2990038A1 (de) Feste pharmazeutische zusammensetzung
CA3157404A1 (en) Novel salt of terphenyl compound
KR102447769B1 (ko) 발베나진 토실산염의 결정형 및 그 제조 방법 및 용도
EP4353723A1 (de) Kristallform von tolbrutinib, herstellungsverfahren dafür und verwendung davon
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
EP4180435A1 (de) Kristallform von upadacitinib, herstellungsverfahren dafür und verwendung davon
SI22750A (sl) Ivabradin hidrobromid
US8124640B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
CN108640910A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP4286377A1 (de) Kristallform von resmetirom, herstellungsverfahren dafür und verwendung davon
KR20200106511A (ko) 아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019008126A1 (en) NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2022036782A1 (zh) 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
US20220267326A1 (en) Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
WO2023208133A1 (zh) 布拉美森盐酸盐的晶型及其制备方法和用途
EP4056182A1 (de) Kristalline form von aprocitentan, herstellungsverfahren dafür und verwendung davon
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
EP4049999A1 (de) Kristallform des hypoxie-induzierbaren faktor-prolyl-hydroxylase-inhibitors
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
WO2023079093A1 (en) Polymorphs of the mesylate salt of linaprazan glurate
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant